PREDICTION OF NEOADJUVANT CHEMOTHERAPY RESPONSE USING DOS

使用 DOS 预测新辅助化疗反应

• 批准号: 8169449
• 负责人: ALBERT Edward CERUSSI
• 金额: $ 2.99万
• 依托单位: UNIVERSITY OF CALIFORNIA-IRVINE
• 依托单位国家: 美国
• 财政年份: 2010
• 资助国家: 美国
• 起止时间: 2010-04-01 至 2011-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8169449
• 关键词: Biochemical; Cancer Patient; Chemotherapy-Oncologic Procedure; Clinical Research; Computer Retrieval of Information on Scientific Projects Database; Diagnostic Procedure; Diffuse; Funding; Grant; Hemoglobin; Institution; Lipids; Mammary Neoplasms; Measurement; Measures; Monitor; Neoadjuvant Therapy; Operative Surgical Procedures; Patients; Research; Research Personnel; Resources; Source; Spectrum Analysis; Staging; Therapeutic; Thick; Tissues; United States National Institutes of Health; Water; Work; chemotherapy; malignant breast neoplasm; optical imaging; response

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. Diffuse Optical Imaging and Spectroscopy (DOI, DOS) are emerging diagnostic techniques that quantitatively measure the concentration of deoxy-hemoglobin, oxy-hemoglobin, water, and lipid in cm-thick tissues. In early-stage clinical studies, DOI and DOS have been used to characterize breast tumor biochemical composition and monitor therapeutic response in neoadjuvant chemotherapy patients. In this work, we investigate whether DOS measurements obtained early in a neoadjuvant chemotherapy regimen can predict final, post-surgical pathological response in breast cancer patients.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 弥漫性光学成像和光谱法（DOI，DOS）是新兴的诊断技术，可在CM-Thick Tissues中定量测量脱氧 - 血红蛋白，氧 - 血红蛋白，水和脂质的浓度。 在早期临床研究中，DOI和DOS已被用来表征乳腺肿瘤的生化组成，并监测新辅助化学疗法患者的治疗反应。 在这项工作中，我们研究了新辅助化疗方案早期获得的DOS测量是否可以预测乳腺癌患者的最终手术后病理反应。